Search
Eplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigationalThis approval was based on positive results demonstrated in the 35-week interim analysis from the Phase 3 NEURO-TTRansform study, where a consistent improvement in the Neuropathy Impairment Score +7 (mNIS … [A262975] Hereditary transthyretin-mediated amyloidosis is caused primarily by pathogenic variants of the TTR gene, leading to the formation and thus accumulation of insoluble and misfolded amyloid in
Synonyms: Ion-ttr-lrxBrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigational[A182186] Currently approved for the treatment of depression, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease, brexpiprazole has also been investigated in other psychiatric … [L46417] Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors.
Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIntravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.
Remimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigationalRemimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. … [A214857] These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed.
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L49560] It is the first RSV vaccine approved for use in pregnant patients to prevent RSV in infants.[L49555]
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies. … [L53743] ITP is an autoimmune disorder characterized by low platelet count.
Cupric oxide
go.drugbank.com/drugs/DB11134ApprovedCopper(II) oxide nanoparticles (NPCuO) have industrial applications as antimicrobial agents in textiles and paints, and catalysts in organic synthesis [A32656]. … Cupric oxide is used as a precursor in many copper-containing products such as wood preservatives and ceramics.
Mixtures: Virt-Pn, Virt-PNSaprisartan
go.drugbank.com/drugs/DB01347ExperimentalSaprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. … It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism [A14009].
Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor BlockersDesvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigational[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. … [A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalImatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. … Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".